Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VE303 in Healthy Adult Volunteers
NCT04236778Phase 1Completed
- Sponsor
- Vedanta Biosciences
- Start
- Nov 2017
- Primary completion
- Mar 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of VE303 in Clostridioides difficile infection (CDI) (10 arms), sponsored by Vedanta Biosciences. Primary endpoints: Incidence of Adverse Events and Tolerability using modified PROMIS questionnaire. Started Nov 2017; status: completed.
02
Drugs
VE303
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT04236778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236778.